glp-1 trial services Prescription by Algorithm: The Ethical and Legal Questions Behind Advertising Glucagon-like peptide-1 receptor agonists and
Description
Consulte a su proveedor de inmediato sobre los sntomas
A 2024 double-blind randomized trial of 156 participants with early Parkinsons disease found that participants receiving a GLP-1 drug, lixisenatide, showed no progression of motor symptoms, compared to a measurable worsening on standard motor scales in the placebo group
If you began at a lower dose and have plateaued, your provider may recommend titrating up to the next level
GET YOUR MACROS NOW WHAT You Have Your Numbers
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ
